Medindia

X

First Clinical Gene Therapy Trial Offers Clues For Muscular Dystrophy

by Tanya Thomas on  October 9, 2010 at 11:05 AM Clinical Trials News   - G J E 4
A clinical trial for gene therapy to replace the genetic defect causing the most common form of muscular dystrophy has revealed that some patients mount an immune response to the dystrophin protein even before they have received the therapy.
 First Clinical Gene Therapy Trial Offers Clues For Muscular Dystrophy
First Clinical Gene Therapy Trial Offers Clues For Muscular Dystrophy
Advertisement

Scientists at the University of North Carolina at Chapel Hill School of Medicine found that the immune systems of a number of patients - once thought to be completely devoid of the dystrophin protein - are actually primed by the prior existence of tiny amounts of this important component of muscle.

Advertisement
"These findings are going to be studied intensely going forward, and should help us to understand how to better tailor our treatment approaches to suit the patients' needs," said R. Jude Samulski, professor of pharmacology and director of the Gene Therapy Center at UNC.

Duchenne muscular dystrophy is a genetic disease that causes progressive muscle weakness, and usually leads to death by the age of twenty from respiratory or cardiac muscle failure. The illness, which primarily affects boys, occurs when a gene on the X chromosome fails to make the essential muscle protein dystrophin.

The use of gene therapy is to inject a smaller yet functional version of the gene - called a minigene - within the viral carrier.

The researchers found that the immune response to the gene varied from patient to patient, perhaps in part because the patients harboured different amounts of "revertant" dystrophin fibers, fibers that have escaped the fate of their mutation. Further studies are needed, but this finding suggests that some patients may benefit from immunosuppression prior to receiving gene therapy.

One lesson from this study suggests that keeping a close eye on the immune-response profiles of patients could help to enhance the success of not just gene therapy, but also other therapies aimed at restoring dystrophin activity.

The study has been published this week in the New England Journal of Medicine.

Source: ANI
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions
sir, my nephew is suffering from muscular dystrophy,it's came from our Easter generation,so please suggest me, what kind treatment can we have
bhupal Monday, July 4, 2011

You May Also Like

Advertisement
View All